Target intelligence / Profile preview

Pterin-4 alpha-carbinolamine dehydratase 1 (PCBD1)

Target
PCBD1
Molecular classification
Enzyme, Transcription cofactor
01

Overview

Pterin-4 alpha-carbinolamine dehydratase 1 (PCBD1) is an enzyme essential in the recycling of **tetrahydrobiopterin (BH4)**, a critical cofactor for enzymes involved in **amino acid metabolism** and **neurotransmitter synthesis**. Besides its enzymatic role, PCBD1 also acts as a **dimerization cofactor (transcriptional coactivator)** for hepatocyte nuclear factors HNF1A (and HNF1B), thereby regulating gene transcription involved in renal magnesium handling (FXYD2), glucose metabolism, and other cellular processes. Mutations in PCBD1 can cause a rare form of **tetrahydrobiopterin deficiency** leading to hyperphenylalaninemia and have been associated with **hypomagnesemia** and, less commonly, glucose intolerance or MODY diabetes. The enzyme forms homodimers or tetramers and interacts with key transcription factors and metabolic enzymes but has no currently known direct therapeutic targeting drugs.

Other names
Pterin-4 alpha-carbinolamine dehydrataseDimerization cofactor of hepatocyte nuclear factor 1-alphaDimerization cofactor of HNF1DCoHPCBDPCDPHSPhenylalanine hydroxylase-stimulating proteinPterin carbinolamine dehydratase4-alpha-hydroxy-tetrahydropterin dehydratase6-pyruvoyl-tetrahydropterin synthase/dimerization cofactor of HNF1 alphaPterin-4a-carbinolamine dehydratase (dimerization cofactor of hepatic nuclear factor 1-alpha)
02

Mechanism of action

Potential mechanisms relate to enzyme supplementation (conceptual, not in clinical use) or modulation of cofactor (tetrahydrobiopterin, BH4) recycling; indirectly, transcriptional modulation via HNF1A/B pathways.

03

Biological functions

Tetrahydrobiopterin (BH4) metabolism and recyclingCofactor for phenylalanine hydroxylase and other aromatic amino acid hydroxylasesTranscriptional coactivation (enhances dimerization/transcriptional activity of hepatocyte nuclear factor 1-alpha and 1-beta, HNF1A/B)Amino acid metabolism (phenylalanine to tyrosine conversion)Regulation of gene transcription, especially FXYD2 and PKHD1
04

Disease associations

Hyperphenylalaninemia (BH4-deficient, D)Tetrahydrobiopterin deficiencyTransient neonatal hyperphenylalaninemiaHypomagnesemiaGlucose intolerance, potential maturity-onset diabetes of the young (MODY diabetes)Pigmentation disorders (in non-human models)Cancer (overexpressed in colon cancer and melanoma lesions)
05

Safety considerations

Generally, loss-of-function mutations cause mild metabolic abnormalities; severe toxicity is not typical.Long-term complications may include hypomagnesemia and MODY diabetes.No reported concerns for direct pharmacological inhibition, as this is not a current drug target.
06

Interacting drugs

No direct therapeutic drugs targeting PCBD1 are currently listed; its function is mainly implicated in rare metabolic disorders which are treated symptomatically (e.g., phenylketonuria therapies target upstream enzymes, not PCBD1 directly)
07

Biomarkers

Elevated phenylalaninePrimapterinuria (accumulation of specific pterin metabolites)Decreased BH4 levelsPossibly hypomagnesemia for monitoring renal complications

Beyond the preview

Go deeper on Pterin-4 alpha-carbinolamine dehydratase 1 (PCBD1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pterin-4 alpha-carbinolamine dehydratase 1 (PCBD1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call